ANKTIVA Market Summary

Key Factors Driving ANKTIVA Growth

1. Rapid commercial uptake in the approved bladder-cancer indication: ANKTIVA (nogapendekin alfa inbakicept-pmnl), an IL-15 receptor agonist, is approved with BCG for adults with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Commercial momentum has been strong: ImmunityBio reported $113 million in full-year 2025 net product revenue, up ~700% year over year, while unit sales increased approximately 750%. In Q2 2026, revenue reached a record $50.7 million, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of sequential revenue growth.

2. Strong efficacy in BCG-unresponsive NMIBC provides a differentiated treatment option: FDA approval was supported by the Phase II/III QUILT-3.032 study. Among 77 efficacy-evaluable patients, ANKTIVA + BCG produced a 62% complete-response rate, with 58% of responders maintaining complete response for at least 12 months and 40% for at least 24 months. This is particularly commercially relevant because BCG-unresponsive high-risk NMIBC represents a difficult-to-treat population with limited bladder-preserving options.

3. Expansion into papillary-only BCG-unresponsive disease could enlarge the US opportunity: In March 2026, the NCCN Clinical Practice Guidelines were updated to include ANKTIVA + BCG for BCG-unresponsive NMIBC with papillary-only disease as a Category 2A recommendation, in addition to the existing CIS population. Furthermore, the FDA accepted ImmunityBio's supplemental BLA for this papillary-disease population and assigned a PDUFA target date of January 6, 2027. A successful label expansion could materially broaden the eligible patient pool beyond CIS.

4. Potential expansion into BCG-naïve first-line NMIBC is a major future catalyst: ImmunityBio has completed enrollment of the pivotal QUILT-2.005 trial evaluating ANKTIVA + BCG in BCG-naïve NMIBC with CIS. The independent data monitoring committee confirmed that sufficient statistical power had been achieved and that no additional enrollment was required. ImmunityBio stated that a supplemental BLA submission was on track for 2026. If approved, moving ANKTIVA from the BCG-unresponsive population into first-line/BCG-naïve disease could substantially expand its addressable market and treatment duration.

5. International expansion is creating additional commercial headroom: ANKTIVA is no longer confined to the US market. By 2026, ImmunityBio reported regulatory approvals/authorizations across five jurisdictions covering approximately 34 countries, with commercial availability expanding into markets including Saudi Arabia. In July 2026, the United Arab Emirates granted ANKTIVA a broad marketing authorization covering BCG-unresponsive NMIBC with CIS and papillary disease as well as metastatic NSCLC. Expansion into Europe, the Middle East and other international markets provides an additional growth lever as reimbursement and commercial infrastructure develop.

ANKTIVA Recent Developments

In May 2026, ImmunityBio, a vertically integrated commercial-stage immunotherapy company, announced that five United States patents have been issued to ImmunityBio covering the combination of its IL-15 receptor agonist ANKTIVA (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin (BCG) for the treatment of cancer.

In February 2026, ImmunityBio, a commercial-stage immunotherapy company announced a partnership with Accord Healthcare to provide access to ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. ImmunityBio also announced the establishment of an Irish subsidiary in Dublin to support the company’s distribution and commercialization strategy throughout Europe.

“ANKTIVA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ANKTIVA for approved indication like Bladder cancer, Non-small cell lung cancer, Lymphopenia; as well as potential indication like Acute myeloid leukaemia, Cervical cancer, Fallopian tube cancer, Gastric cancer, Glioblastoma, Hereditary nonpolyposis colorectal cancer, and HIV infections in the 7MM. A detailed picture of ANKTIVA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ANKTIVA for approved and potential indications. The ANKTIVA market report provides insights about ANKTIVA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ANKTIVA performance, future market assessments inclusive of the ANKTIVA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ANKTIVA sales forecasts, along with factors driving its market.

ANKTIVA Drug Summary

ANKTIVA is a first-in-class interleukin-15 (IL-15) receptor agonist developed by ImmunityBio that consists of an IL-15N72D variant bound to an IL-15 receptor-alpha Fc fusion protein. By activating the IL-15 pathway, ANKTIVA promotes the proliferation and activation of natural killer (NK) cells, CD8+ T cells, and memory T cells without stimulating immunosuppressive regulatory T cells, thereby enhancing antitumor immune responses. It is administered intravesically in combination with Bacillus Calmette-Guérin (BCG) and is approved for adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The treatment is delivered directly into the bladder through a catheter, with an induction regimen of once-weekly administration for six weeks followed by maintenance therapy in eligible patients. The report provides ANKTIVA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ANKTIVA Market Report

The report provides insights into:

• A comprehensive product overview including the ANKTIVA MoA, description, dosage and administration, research and development activities in approved indications like Bladder cancer, Non-small cell lung cancer, Lymphopenia; as well as potential indication like Acute myeloid leukaemia, Cervical cancer, Fallopian tube cancer, Gastric cancer, Glioblastoma, Hereditary nonpolyposis colorectal cancer, and HIV infections.
• Elaborated details on ANKTIVA regulatory milestones and other development activities have been provided in ANKTIVA market report.
• The report also highlights ANKTIVA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ANKTIVA market report also covers the patents information, generic entry and impact on cost cut.
• The ANKTIVA market report contains current and forecasted ANKTIVA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ANKTIVA market report also features the SWOT analysis with analyst views for ANKTIVA in approved and potential indications.

Methodology

The ANKTIVA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ANKTIVA Analytical Perspective by DelveInsight

• In-depth ANKTIVA Market Assessment

This ANKTIVA sales market forecast report provides a detailed market assessment of ANKTIVA for approved indication like Bladder cancer, Non-small cell lung cancer, Lymphopenia; as well as potential indication like Acute myeloid leukaemia, Cervical cancer, Fallopian tube cancer, Gastric cancer, Glioblastoma, Hereditary nonpolyposis colorectal cancer, and HIV infections in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ANKTIVA sales data uptil 2034.

• ANKTIVA Clinical Assessment

The ANKTIVA market report provides the clinical trials information of ANKTIVA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ANKTIVA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ANKTIVA Market Potential & Revenue Forecast

• Projected market size for the ANKTIVA and its key indications
• Estimated ANKTIVA sales potential (ANKTIVA peak sales forecasts)
• ANKTIVA Pricing strategies and reimbursement landscape

ANKTIVA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ANKTIVA Market positioning compared to existing treatments
• ANKTIVA Strengths & weaknesses relative to competitors

ANKTIVA Regulatory & Commercial Milestones

• ANKTIVA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ANKTIVA Clinical Differentiation

• ANKTIVA Efficacy & safety advantages over existing drugs
• ANKTIVA Unique selling points

ANKTIVA Market Report Highlights

• In the coming years, the ANKTIVA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ANKTIVA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ANKTIVA’s dominance.
• Other emerging products for Bladder cancer, Non-small cell lung cancer, Lymphopenia; as well as potential indication like Acute myeloid leukaemia, Cervical cancer, Fallopian tube cancer, Gastric cancer, Glioblastoma, Hereditary nonpolyposis colorectal cancer, and HIV infections are expected to give tough market competition to ANKTIVA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ANKTIVA in approved and potential indications.
• Analyse ANKTIVA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ANKTIVA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ANKTIVA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ANKTIVA? How strong is ANKTIVA’s clinical and commercial performance?
• What is ANKTIVA’s clinical trial status in each individual indications such as Bladder cancer, Non-small cell lung cancer, Lymphopenia; as well as potential indication like Acute myeloid leukaemia, Cervical cancer, Fallopian tube cancer, Gastric cancer, Glioblastoma, Hereditary nonpolyposis colorectal cancer, and HIV infections and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ANKTIVA Manufacturers?
• What are the key designations that have been granted to ANKTIVA for approved and potential indications? How are they going to impact ANKTIVA’s penetration in various geographies?
• What is the current and forecasted ANKTIVA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ANKTIVA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ANKTIVA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ANKTIVA? What is the duration of therapy and what are the geographical variations in cost per patient?